Wellington Management Group Portfolio holdings
Wellington Management Group, founded in 1928 by Walter L. Morgan and headquartered in Boston, Massachusetts, is one of the world’s largest independent asset management firms, overseeing trillions in assets for a diverse client base including pension funds, endowments, and mutual fund investors. Renowned for its active management approach, Wellington offers a broad range of investment strategies across equities, fixed income, multi-asset, and alternative investments, emphasizing deep research and long-term partnerships with clients. The firm gained early fame for launching the Wellington Fund, one of the first balanced mutual funds, and has since maintained a reputation for disciplined, collaborative portfolio management. With a global presence and a focus on customized solutions, Wellington remains a trusted name in institutional and retail investing.
Top Buys
| 1 |
Alphabet (Google) Class A
GOOGL
|
$1.77B |
| 2 |
Microsoft
MSFT
|
$1.65B |
| 3 |
NVIDIA
NVDA
|
$1.47B |
| 4 |
Gilead Sciences
GILD
|
$1.13B |
| 5 |
Kroger
KR
|
$1.03B |
Top Sells
| 1 |
Procter & Gamble
PG
|
$1.34B |
| 2 |
Apple
AAPL
|
$1.23B |
| 3 |
United Parcel Service
UPS
|
$1.09B |
| 4 |
American Express
AXP
|
$999M |
| 5 |
JPMorgan Chase
JPM
|
$969M |
Sector Composition
| 1 | Technology | 24.89% |
| 2 | Financials | 15.95% |
| 3 | Healthcare | 15.37% |
| 4 | Consumer Discretionary | 9.68% |
| 5 | Industrials | 9.05% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1601
Acrivon Therapeutics
ACRV
$41.8M
| $1.06M | ﹤0.01% |
888,130
| – | – |
|
1602
Descartes Systems
DSGX
$9.26B
| $1.05M | ﹤0.01% |
10,384
+27
| +0.3% | +$2.74K |
|
1603
Astria Therapeutics
ATXS
$424M
| $1.04M | ﹤0.01% |
193,749
+41,138
| +27% | +$221K |
|
1604
Global Payments
GPN
$21.3B
| $1.03M | ﹤0.01% |
12,852
-372,371
| -97% | -$29.8M |
|
|
LENZ
1605
LENZ Therapeutics
LENZ
$1.2B
| $1.02M | ﹤0.01% |
34,827
+4,339
| +14% | +$127K |
|
1606
Heron Therapeutics
HRTX
$201M
| $1.02M | ﹤0.01% |
493,083
+5,841
| +1% | +$12.1K |
|
1607
Monte Rosa Therapeutics
GLUE
$305M
| $1.01M | ﹤0.01% |
224,818
+37,087
| +20% | +$167K |
|
1608
MoonLake Immunotherapeutics
MLTX
$3.77B
| $1.01M | ﹤0.01% |
21,390
-10,773
| -33% | -$508K |
|
1609
Catalyst Pharmaceutical
CPRX
$2.48B
| $1.01M | ﹤0.01% |
46,359
-2,088
| -4% | -$45.3K |
|
1610
Abeona Therapeutics
ABEO
$353M
| $991K | ﹤0.01% |
174,514
+21,393
| +14% | +$122K |
|
1611
ICL Group
ICL
$7.85B
| $987K | ﹤0.01% |
143,929
-344,408
| -71% | -$2.36M |
|
1612
Tyra Biosciences
TYRA
$674M
| $986K | ﹤0.01% |
103,078
-1,009
| -1% | -$9.66K |
|
1613
Equity Lifestyle Properties
ELS
$12B
| $980K | ﹤0.01% |
15,897
+293
| +2% | +$18.1K |
|
|
GAP
1614
The Gap, Inc.
GAP
$8.83B
| $979K | ﹤0.01% |
+44,891
| New | +$979K |
|
1615
Altimmune
ALT
$334M
| $975K | ﹤0.01% |
251,866
+26,912
| +12% | +$104K |
|
1616
Absci
ABSI
$368M
| $972K | ﹤0.01% |
378,261
+55,142
| +17% | +$142K |
|
1617
Olema Pharmaceuticals
OLMA
$570M
| $971K | ﹤0.01% |
228,021
-1,245,658
| -85% | -$5.31M |
|
1618
Utilities Select Sector SPDR Fund
XLU
$20.7B
| $965K | ﹤0.01% |
11,820
-35,032
| -75% | -$2.86M |
|
1619
Chemed
CHE
$6.79B
| $958K | ﹤0.01% |
1,967
-47
| -2% | -$22.9K |
|
1620
Trevi Therapeutics
TRVI
$854M
| $941K | ﹤0.01% |
171,982
+44,530
| +35% | +$244K |
|
1621
Afya
AFYA
$1.37B
| $932K | ﹤0.01% |
52,203
| – | – |
|
1622
OP Bancorp
OPBK
$212M
| $913K | ﹤0.01% |
70,299
| – | – |
|
1623
Compass Therapeutics
CMPX
$590M
| $905K | ﹤0.01% |
348,040
+125,535
| +56% | +$326K |
|
1624
Fulcrum Therapeutics
FULC
$414M
| $870K | ﹤0.01% |
+126,402
| New | +$870K |
|
1625
iShares MSCI Australia ETF
EWA
$1.53B
| $866K | ﹤0.01% |
+32,902
| New | +$866K |
|